By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the last 12 months, three Anika Therapeutics, Inc. company insiders added shares at market prices, about $264,000 in total, and none of them sold.
Biggest single buyer: Griffin Stephen D., CEO, with roughly $150,000. Notably, at least one C-suite executive was among the buyers.
Quarter by quarter: 2 quarters in a row of net buying by insiders. Insiders bought in 2 of the last 7 full quarters. On the institutional side, 133 funds reported holding ANIK at the end of Q2 2026, and more funds bought than sold.
Are insiders buying or selling ANIK stock?
In the last 12 months Anika Therapeutics, Inc. insiders made open-market purchases worth about $264,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in ANIK?
The most recent open-market insider trade in ANIK was filed on 2026-08-05.
How many institutions own ANIK?
133 investment managers reported holding ANIK in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded ANIK?
No congressional trades in ANIK were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).